Enalozid (enalapril, hydrochlorothiazide) tablets 12.5 mg. №30

$11.00

Manufacturer: Ukraine

Purpose: Enalozid treats hypertension by blocking angiotensin-converting enzyme and promoting diuresis.

SKU: MED58111 Category:

Description

Enalozid (enalapril, hydrochlorothiazide) tablets 12.5 mg. №30

Ingredients

Active substances: Enalapril, Hydrochlorothiazide

Dosage

Recommended dose: 1 tablet once a day.

Indications

Enalozid tablets are indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled with monotherapy.

Contraindications

Do not use Enalozid tablets if you are allergic to any of the ingredients, have a history of angioedema related to previous treatment with ACE inhibitors, or if you are pregnant.

Directions

Take Enalozid tablets orally with or without food, as directed by your healthcare provider.

Scientific Evidence

Enalapril, an ACE inhibitor, and hydrochlorothiazide, a thiazide diuretic, are well-studied medications for hypertension. Research has shown that the combination of these two drugs can lead to a greater reduction in blood pressure compared to monotherapy. A study published in the Journal of Clinical Hypertension demonstrated the efficacy of enalapril and hydrochlorothiazide in lowering blood pressure and reducing cardiovascular events in hypertensive patients.

Additional Information

It is important to regularly monitor blood pressure while taking Enalozid tablets and to report any side effects to your healthcare provider. Avoid consuming alcohol while on this medication as it can further lower blood pressure.

Pharmacological Effects: Enalapril works by inhibiting the angiotensin-converting enzyme, leading to vasodilation and reduced aldosterone secretion. Hydrochlorothiazide promotes diuresis by inhibiting sodium reabsorption in the distal convoluted tubule.

Clinical Trials: Clinical trials have shown that the combination of enalapril and hydrochlorothiazide is effective in reducing blood pressure and improving cardiovascular outcomes in hypertensive patients. A meta-analysis published in the Journal of Hypertension concluded that the combination therapy is well-tolerated and significantly reduces blood pressure levels.